Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
AC Immune S.A. (ACIU)
AC Immune S.A. (ACIU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

AC Immune S.A. EPFL INNOVATION PARK BUILDING B 1015 LAUSANNE V8 1015 CHE

www.acimmune.com P: 41-21-345-9121 F: +41 213459120

Description:

AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland.

Key Statistics

Overview:

Market Capitalization, $K 282,060
Enterprise Value, $K 248,960
Shares Outstanding, K 84,449
Annual Sales, $ 4,120 K
Annual Net Income, $ -74,140 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -17,140 K
EBIT, $ -74,800 K
EBITDA, $ -72,330 K
60-Month Beta 1.02
% of Insider Shareholders 4.60%
% of Institutional Shareholders 19.17%
Float, K 80,564
% Float 95.40%
Short Volume Ratio 0.70

Growth:

1-Year Return 40.34%
3-Year Return -55.99%
5-Year Return -26.75%
5-Year Revenue Growth -79.99%
5-Year Earnings Growth -196.67%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.20 on 11/03/23
Latest Earnings Date 03/21/24
Earnings Per Share ttm -0.89
EPS Growth vs. Prev Qtr 9.09%
EPS Growth vs. Prev Year -17.65%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ACIU Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -46.44%
Return-on-Assets % -41.64%
Profit Margin % -1,799.51%
Debt/Equity 0.00
Price/Sales 246,707.48
Price/Cash Flow N/A
Price/Book 1.82
Book Value/Share 1.70
Interest Coverage -199.35
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar